Cipla Limited Appoints Vice-Chairman, Approves Investment and Amalgamation
Cipla Limited announced several key developments following a board meeting held on March 19, 2026. Mr. P R Ramesh, Lead Independent Director, has been designated as Vice-Chairman, effective April 1, 2026. Robert Stewart, an Independent Director, will not seek re-appointment upon the completion of his term on May 13, 2026.The company approved an investment of USD 100 million in the equity share capital of Cipla (EU) Limited, a wholly-owned subsidiary, to provide financial assistance to InvaGen Pharmaceuticals Inc., another wholly-owned subsidiary of Cipla (EU) Limited. This investment will support capital expenditure, working capital requirements, and general corporate purposes.
Cipla also approved a Scheme of Amalgamation of Inzpera Healthsciences Limited, a wholly-owned subsidiary, with the company. The amalgamation requires approvals under the Companies Act, 2013, including approval from the National Company Law Tribunal, Mumbai. Cipla anticipates the amalgamation will not have a material impact on its financials.
Financial Details of Cipla (EU) Limited
The following table summarizes the financial details of Cipla (EU) Limited:
| Particulars | Details | Details |
|---|---|---|
| Turnover | 3.76 (USD crore) | |
| Profit After Tax | 0.60 (USD crore) | |
| FY 2024-25 Turnover | 3.76 (USD crore) | |
| FY 2023-24 Turnover | 2.51 (USD crore) | |
| FY 2022-23 Turnover | 2.91 (USD crore) |
Amalgamation Details
The amalgamation does not involve any consideration, as Inzpera is a wholly-owned subsidiary of Cipla. All shares of Inzpera will be cancelled upon the scheme's effectiveness.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.